Welcome to BioSeeker Group!

Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Additional Information

Published Date Aug 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1755
PDF Fact Sheet View Fact Sheet for the report Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $1,950.00

Special Price: $975.00

Quick Overview

This report represents a new and unique way of stratifying and analyzing the global breast cancer drug pipeline towards personalized medicine.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others.

    To find out more about Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report will excel your competitive awareness and decrease your decision making time in managing breast cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 470 breast cancer drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer.

BioSeeker has applied its unique drug assessment methodology to stratify the breast cancer drug pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of breast cancer drugs is split between the approximately one third which have unique drug target strategies and the other two thirds which have head-to-head target competing drugs in 61 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the breast cancer drugs in general.

* Nine out of every ten drug target strategies in Phase II and three out of every four in Phase III development are new to breast cancer drugs.

* The greatest number of new target strategies are found in Phase II (35%) and Preclinical (17%) development.

* Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of breast cancer drugs, which represent almost 80% of the entire pipeline.

* Besides Reformulated drugs, it is Cell therapies, Peptides and Antibodiesbased breast cancer drugs that have the highest cross-over of drug target strategies with other compound strategies.

* The highest number of described drug target strategies of breast cancer drugs belongs to Pfizer, AstraZeneca and Hoffmann-La Roche.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any breast cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 23
4.2 List of Tables 23
5 Introduction 32
5.1 The Scope of this Report 32
5.2 Definitions 35
5.3 Abbreviations 35
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 36
6.1 Drug Repositioning in Oncology 36
6.2 Introduction to Targets of Breast Cancer Drugs 37
6.2.1 Acid Phosphatase Activity Targets 45
6.2.2 Auxiliary Transport Protein Activity Targets 46
6.2.3 Catalytic Activity Targets 47
6.2.4 Cell Adhesion Molecule Activity Targets 61
6.2.5 Chaperone Activity Targets 76
6.2.6 Chemokine Activity Targets 81
6.2.7 Complement Activity Targets 83
6.2.8 Cysteine-type Peptidase Activity Targets 86
6.2.9 Cytokine Activity Targets 94
6.2.10 DNA Binding Targets 102
6.2.11 DNA Repair Protein Targets 104
6.2.12 DNA Topoisomerase Activity Targets 106
6.2.13 DNA-directed DNA Polymerase Activity Targets 111
6.2.14 Extracellular Ligand-gated Ion Channel Activity Targets 112
6.2.15 Extracellular Matrix Structural Constituent Targets 114
6.2.16 G-protein Coupled Receptor Activity Targets 115
6.2.17 Glutathione Transferase Activity Targets 125
6.2.18 Growth Factor Activity Targets 127
6.2.19 Growth Factor Binding Targets 134
6.2.20 Hormone Activity Targets 135
6.2.21 Intracellular Ligand-gated Ion Channel Activity Targets 136
6.2.22 Ion Channel Activity Targets 137
6.2.23 Isomerase Activity Targets 138
6.2.24 Kinase Activity Targets 139
6.2.25 Kinase Binding Targets 151
6.2.26 Kinase Regulator Activity Targets 152
6.2.27 Ligand-dependent Nuclear Receptor Activity Targets 156
6.2.28 Ligase Activity Targets 159
6.2.29 Lipid Kinase Activity Targets 166
6.2.30 Lipid Phosphatase Activity Targets 175
6.2.31 Metallopeptidase Activity Targets 176
6.2.32 Molecular Function Unknown Targets 180
6.2.33 Motor Activity Targets 190
6.2.34 Oxidoreductase Activity Targets 192
6.2.35 Peptidase Activity Targets 201
6.2.36 Peptide Hormone Targets 210
6.2.37 Peroxidase Activity Targets 211
6.2.38 Phosphoric Diester Hydrolase Activity Targets 212
6.2.39 Protein Binding Targets 215
6.2.40 Protein Serine/Threonine Kinase Activity Targets 220
6.2.41 Protein Threonine/Tyrosine Kinase Activity Targets 258
6.2.42 Protein-tyrosine Kinase Activity Targets 263
6.2.43 Receptor Activity Targets 274
6.2.44 Receptor Binding Targets 291
6.2.45 Receptor Signaling Complex Scaffold Activity Targets 299
6.2.46 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 303
6.2.47 RNA Binding Targets 305
6.2.48 RNA-directed DNA Polymerase Activity Targets 306
6.2.49 Serine-type Peptidase Activity Targets 307
6.2.50 Structural Constituent of Cytoskeleton Targets 310
6.2.51 Structural Molecule Activity Targets 313
6.2.52 Superoxide Dismutase Activity Targets 315
6.2.53 T Cell Receptor Activity Targets 317
6.2.54 Transcription Factor Activity Targets 318
6.2.55 Transcription Regulator Activity Targets 348
6.2.56 Transferase Activity Targets 359
6.2.57 Translation Regulator Activity Targets 362
6.2.58 Transmembrane Receptor Activity Targets 363
6.2.59 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 367
6.2.60 Transporter Activity Targets 415
6.2.61 Voltage-gated Ion Channel Activity Targets 422
6.2.62 Other Targets 423
6.3 Mutation Profiles of Breast Cancer Drug Targets 426
6.3.1 Targets of Breast Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 426
6.4 Breast Cancer Therapeutics is Stimulated by Available Structure Data on Targets 432
6.5 Target-Target Interactions among Identified Targets of Breast Cancer Drugs 437
6.6 The Drug-Target Competitive Landscape 442
6.7 Protein Expression Levels of Identified Targets of Breast Cancer Drugs 447
6.8 Pathway Assessment of Breast Cancer Drugs 451
6.8.1 Tools for Analysis of Cancer Pathways 452
6.8.2 Pathway Assessment 453
7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development 523
7.1 Marketed: New and Unique Drug Target Strategies of Breast Cancer Drugs 526
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 528
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 530
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 537
7.5 Preclinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 541
7.6 Drug Target Strategies of Suspended or Terminated Breast Cancer Drugs 545
7.7 Target Strategy Development Profiles of Breast Cancer Drugs 549
7.7.1 Marketed 554
7.7.2 Phase III 574
7.7.3 Phase II 583
7.7.4 Phase I 660
7.7.5 Preclinical 695
7.7.6 No Data 734
7.7.7 Suspended 735
7.7.8 Ceased 738
7.8 The Competition Through Close Mechanistic Approximation of Breast Cancer Drugs 786
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy 798
8.1 Small Molecules 800
8.1.1 Background 800
8.1.2 Target Strategies of Small Molecule Drugs 801
8.2 Peptide & Protein Drugs 817
8.2.1 Background 817
8.2.2 Target Strategies of Peptide and Protein Drugs 818
8.3 Antibodies 824
8.3.1 Background 824
8.3.2 Target Strategies of Antibody Drugs 824
8.4 Nucleic Acid Therapies 829
8.4.1 Background 829
8.4.2 Target Strategies of Nucleic Acid Drugs 830
8.5 Cell & Gene Therapy 832
8.5.1 Background 832
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 833
8.6 Drug Delivery and Nanotechnology 838
8.6.1 Background 838
8.6.2 Target Strategies of Reformulated Drugs 838
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 842
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator 851
9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 857
9.2 Company Facts and Ranking 860
9.3 Competitive Fall-Out Assessment 867
9.4 A&G Pharmaceutical 869
9.5 Abbott 871
9.6 Abiogen 876
9.7 Access 880
9.8 Adherex 883
9.9 Advanomics 885
9.10 Advaxis 889
9.11 AEgera 893
9.12 AEterna Zentaris 895
9.13 Affibody 897
9.14 Affimed Therapeutics 901
9.15 Alchemia 904
9.16 Alethia Biotherapeutics 910
9.17 Allos Therapeutics 912
9.18 Alnis Biosciences 914
9.19 AlphaVax 918
9.20 Alseres Pharmaceuticals 923
9.21 Amgen 926
9.22 AngioChem 934
9.23 Antisoma 938
9.24 Aphios 943
9.25 Ariad 948
9.26 ArQule 951
9.27 Array BioPharma 955
9.28 Ascend Therapeutics 960
9.29 Ascepion Pharmaceuticals 963
9.30 Astellas 965
9.31 Astex Pharmaceuticals 970
9.32 AstraZeneca 974
9.33 Attenuon 985
9.34 AVI BioPharma 987
9.35 Basilea Pharmaceutica 989
9.36 Bavarian Nordic 993
9.37 Bayer 997
9.38 Beta Pharma 1004
9.39 Betagenon 1007
9.40 Biogen Idec 1009
9.41 BioMarin 1013
9.42 Bionovo 1015
9.43 BioSante 1018
9.44 Biotecnol 1021
9.45 Boehringer Ingelheim 1025
9.46 Bristol-Myers Squibb 1028
9.47 BTG 1039
9.48 Callisto Pharmaceuticals 1044
9.49 Cancer Research Technology 1048
9.50 Cel-Sci 1052
9.51 Celgene 1054
9.52 Cell Therapeutics 1059
9.53 Celldex Therapeutics 1065
9.54 Celltrion 1067
9.55 Celsion 1071
9.56 Celtic Pharma 1075
9.57 Center of Molecular Immunology 1077
9.58 Chemokine Therapeutics 1080
9.59 Chiesi 1083
9.60 Chong Kun Dang 1086
9.61 CompleGen 1090
9.62 Curis 1092
9.63 Cyclacel 1095
9.64 Cylene Pharmaceuticals 1097
9.65 Cynvec 1099
9.66 CytImmune Sciences 1101
9.67 Cytokinetics 1105
9.68 CytRx 1108
9.69 Daiichi Sankyo 1112
9.70 Dainippon Sumitomo Pharma 1117
9.71 Debiopharm 1121
9.72 Dendreon 1124
9.73 Domainex 1129
9.74 Dong-A 1131
9.75 Dongkook Pharm 1135
9.76 Douglas 1138
9.77 ECI 1141
9.78 Eisai 1143
9.79 Elara Pharmaceuticals 1148
9.80 ElexoPharm 1151
9.81 Eli Lilly 1153
9.82 Endoceutics 1161
9.83 Enkam Pharmaceuticals 1164
9.84 EntreMed 1166
9.85 Enzon 1168
9.86 Epeius Biotechnologies 1171
9.87 EpiCept 1173
9.88 Epizyme 1177
9.89 Esperance Pharmaceuticals 1179
9.90 Etubics 1181
9.91 Eucodis 1185
9.92 Exelixis 1188
9.93 Expression Drug Designs 1195
9.94 Formula Pharmaceuticals 1197
9.95 Fresenius 1200
9.96 Galectin Therapeutics 1204
9.97 Galena Biopharma 1208
9.98 Genentech 1213
9.99 Generex 1217
9.100 Genmab 1221
9.101 Genta 1226
9.102 GenVec 1228
9.103 Geron 1230
9.104 Gilead Sciences 1233
9.105 GlaxoSmithKline 1237
9.106 GlyTag 1244
9.107 Got-a-Gene 1246
9.108 Gradalis 1250
9.109 Harbor BioSciences 1252
9.110 Heidelberg Pharma 1255
9.111 Hoffmann-La Roche 1258
9.112 Hospira 1271
9.113 Idera Pharmaceuticals 1275
9.114 Immunocore 1278
9.115 ImmunoGen 1281
9.116 Immunomedics 1285
9.117 ImmuPharma 1289
9.118 Immutep 1291
9.119 Incyte Corporation 1293
9.120 Inex 1296
9.121 Infinity Pharmaceuticals 1300
9.122 Innate Pharma 1303
9.123 InNexus Biotechnology 1305
9.124 Inovio 1309
9.125 Insmed 1311
9.126 Insys Therapeutics 1314
9.127 Intarcia Therapeutics 1320
9.128 Intezyne Technologies 1323
9.129 Intradigm 1327
9.130 Introgen Therapeutics 1330
9.131 Ipsen 1334
9.132 Isis Pharmaceuticals 1338
9.133 Jina Pharmaceuticals 1340
9.134 Johnson & Johnson 1343
9.135 Kiadis 1345
9.136 Kinex 1348
9.137 Kyowa Hakko Kirin 1350
9.138 Leo 1356
9.139 Ligand 1358
9.140 Lorus Therapeutics 1362
9.141 MacroGenics 1364
9.142 Marillion Pharmaceuticals 1368
9.143 Marina Biotech 1371
9.144 Meda 1374
9.145 Medarex 1379
9.146 MediGene 1382
9.147 MedImmune 1386
9.148 Mediolanum 1389
9.149 Menarini 1392
9.150 Merck & Co 1396
9.151 Merck KGaA 1401
9.152 Merrimack 1403
9.153 MetaMol Theranostics 1407
9.154 Mologen 1410
9.155 Nektar Therapeutics 1413
9.156 Nemod Biotherapeutics 1416
9.157 Neurocrine Biosciences 1419
9.158 NexGenix Pharmaceuticals 1421
9.159 Nidus Laboratories 1425
9.160 NIH – The US National Institute of Health 1429
9.161 Nimbus Discovery 1432
9.162 Nippon Kayaku 1434
9.163 Non-industrial Source 1437
9.164 Novartis 1441
9.165 Novogen 1453
9.166 Oasmia 1455
9.167 OncoGenex Pharmaceuticals 1457
9.168 Oncolix 1462
9.169 OncoMune 1465
9.170 Onconova 1469
9.171 Oncothyreon 1472
9.172 Oncozyme Pharma 1476
9.173 Orion Pharma 1478
9.174 OSI Pharmaceuticals 1481
9.175 Oxford BioMedica 1486
9.176 Pacific Biotech 1488
9.177 Paladin Labs 1491
9.178 PanaGin 1494
9.179 Pantarhei Bioscience 1496
9.180 Peregrine Pharmaceuticals 1499
9.181 Pfizer 1501
9.182 Pharmacyclics 1515
9.183 PharmaGap 1517
9.184 PharmaMar 1519
9.185 Pharmexa 1523
9.186 PheneX 1528
9.187 Philogen 1530
9.188 Pierre Fabre 1532
9.189 Piramal 1535
9.190 ProStrakan 1537
9.191 PTC Therapeutics 1539
9.192 R&R 1542
9.193 Radient Pharmaceuticals 1545
9.194 Raptor Pharmaceutical 1547
9.195 Receptor BioLogix 1549
9.196 Regeneron 1552
9.197 Regulon 1555
9.198 RESprotect 1557
9.199 Rigel 1559
9.200 Samyang 1561
9.201 Sanofi 1566
9.202 Santaris Pharma 1573
9.203 Sareum 1575
9.204 Savient Pharmaceuticals 1577
9.205 Schering-Plough 1580
9.206 SEEK 1583
9.207 Selvita 1586
9.208 Semafore Pharmaceuticals 1588
9.209 Shenogen 1590
9.210 Sigma-Tau 1594
9.211 Sirnaomics 1597
9.212 SRI International 1599
9.213 Sun Pharma Advanced Research 1604
9.214 Supratek Pharma 1608
9.215 Synageva BioPharma 1612
9.216 Synta Pharmaceuticals 1616
9.217 Taiho 1618
9.218 Taiwan Liposome Company 1622
9.219 Takeda 1626
9.220 Tapestry Pharmaceuticals 1628
9.221 TapImmune 1632
9.222 Targa Therapeutics 1634
9.223 Tau Therapeutics 1636
9.224 Taxolog 1640
9.225 Telik 1645
9.226 Teva 1649
9.227 Thallion Pharmaceuticals 1655
9.228 Therion Biologics 1657
9.229 to-BBB 1659
9.230 TopoTarget 1663
9.231 Tragara Pharmaceuticals 1666
9.232 Transgene 1668
9.233 Trion Pharma 1670
9.234 Vaccinex 1672
9.235 Vaxon Biotech 1674
9.236 Verastem 1677
9.237 Vernalis 1681
9.238 Vical 1684
9.239 Vion Pharmaceuticals 1687
9.240 VioQuest 1690
9.241 ViroMed 1693
9.242 ViroTarg 1697
9.243 Wilex 1699
9.244 Wyeth 1701
9.245 Xerion 1704
9.246 Xoma 1707
9.247 Yakult Honsha 1710
9.248 YM BioSciences 1713
9.249 Zensun 1716
9.250 Zydus Cadila 1719
10 Disclaimer 1724
11 Drug Index 1725
12 Company Index 1742

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Breast Cancer Drugs 441
Figure 2: The Drug-Target Competitive Landscape of Breast Cancer Drugs - Large Cluster 443
Figure 3: The Drug-Target Competitive Landscape Breast Cancer Drugs - Smaller Clusters 444
Figure 4: Head-to-Head Targeting Competitive Landscape of Breast Cancer Drugs – Larger Clusters 445
Figure 5: Head-to-Head Targeting Competitive Landscape of Breast Cancer Drugs – Smaller Clusters 446
Figure 6: Distribution of Compound Strategies among Breast Cancer Drugs 842
Figure 7: Primary Sub-cellular Localization of Drug Targets 843
Figure 8: Number of Companies per Ranking Level 862

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Breast Cancer Drug Pipeline by Stage of Development 32
Table 3: Head to Head Target Competition among Breast Cancer Drugs 32
Table 4: Overview of Drug Target Strategy Themes 37
Table 5: Terminally Ceased Targets of Breast Cancer Drugs 38
Table 6: Official Gene Symbol to Target Profle 39
Table 7: Mutation Frequencies of Breast Cancer Drug Targets 427
Table 8: Identity of Drug Targets with Available Biological Structures 432
Table 9: Number of Target-Target Interactions among Targets of Breast Cancer Drugs 438
Table 10: Available Protein Expression Profiles of Breast Cancer Drug Targets 447
Table 11: Pathway Summary 453
Table 12: Drug Targets without any Identified Assigned Pathways 453
Table 13: Pathway Profiles According to BioCarta of Breast Cancer Drug Targets 455
Table 14: Pathway Profiles According to KEGG of Breast Cancer Drug Targets 481
Table 15: Pathway Profiles According to NetPath of Breast Cancer Drug Targets 512
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 523
Table 17: Top Competitive Target Strategies of Breast Cancer Drugs 524
Table 18: New and Unique Target Strategies of Marketed Breast Cancer Drugs 526
Table 19: The Competition Through Close Mechanistic Approximation Between Breast Cancer Drugs Being Marketed 527
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Breast Cancer Drugs 528
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Breast Cancer Drugs 529
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Breast Cancer Drugs 530
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Breast Cancer Drugs 534
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Breast Cancer Drugs 537
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Breast Cancer Drugs 539
Table 26: New and Unique Target Strategies in Preclinical Development of Breast Cancer Drugs 541
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Breast Cancer Drugs 543
Table 28: Target Strategies of No Data, Suspended or Terminated Breast Cancer Drugs 545
Table 29: Connecting Target Strategy with Its Profile Identification Number 549
Table 30: The Competition Through Close Mechanistic Approximation Among Breast Cancer Drugs 786
Table 31: Overview of Compound Strategy Competition Among Breast Cancer Drugs 799
Table 32: Overview of the Competitive Landscape of Small Molecule Based Breast Cancer Drugs 801
Table 33: Competitive Comparison of Target Strategies of Small Molecule Breast Cancer Drugs 802
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Breast Cancer Drugs 809
Table 35: Overview of the Competitive Landscape of Peptide Based Breast Cancer Drugs 818
Table 36: Competitive Comparison of Target Strategies of Peptide Based Breast Cancer Drugs 819
Table 37: Pursued Target Strategies of Peptide Based Breast Cancer Drugs 819
Table 38: Overview of the Competitive Landscape of Protein Based Breast Cancer Drugs 821
Table 39: Competitive Comparison of Target Strategies of Protein Based Breast Cancer Drugs 822
Table 40: Pursued Target Strategies of Protein Based Breast Cancer Drugs 822
Table 41: Overview of the Competitive Landscape of Antibody Based Breast Cancer Drugs 824
Table 42: Competitive Comparison of Target Strategies of Antibody Based Breast Cancer Drugs 825
Table 43: Pursued Target Strategies of Antibody Based Breast Cancer Drugs 826
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Breast Cancer Drugs 830
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Breast Cancer Drugs 831
Table 46: Pursued Target Strategies of Nucleic Acid Based Breast Cancer Drugs 831
Table 47: Potential Forms of Cell Therapy 832
Table 48: Vectors in Gene Therapy 833
Table 49: Overview of the Competitive Landscape of Cell Therapy Based Breast Cancer Drugs 833
Table 50: Competitive Comparison of Target Strategies of Cell Therapy Based Breast Cancer Drugs 834
Table 51: Pursued Target Strategies of Cell Therapy Based Breast Cancer Drugs 834
Table 52: Overview of the Competitive Landscape of Gene Therapy Based Breast Cancer Drugs 835
Table 53: Competitive Comparison of Target Strategies of Gene Therapy Based Breast Cancer Drugs 836
Table 54: Pursued Target Strategies of Gene Therapy Based Breast Cancer Drugs 836
Table 55:Overview of the Competitive Landscape of Reformulated Breast Cancer Drugs 838
Table 56: Competitive Comparison of Target Strategies of Reformulated Breast Cancer Drugs 839
Table 57: Pursued Target Strategies of Reformulated Breast Cancer Drugs 840
Table 58: Compound Strategies based on Sub-Cellular Localization of Breast Cancer Drug Targets 843
Table 59: Competitive Summary by Investigator of Breast Cancer Drug Development 851
Table 60: Summary Table of Corporate Changes in the Competitive Landscape of Breast Cancer Drug Development 857
Table 61: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 861
Table 62: Example of a Competitive Fall-Out Table (Targeting TYMS/Modified) 867
Table 63: A&G Pharmaceutical’s Included Breast Cancer Drugs and Competitive Fall-Out 870
Table 64: Abbott’s Included Breast Cancer Drugs and Competitive Fall-Out 873
Table 65: Abiogen’s Included Breast Cancer Drugs and Competitive Fall-Out 879
Table 66: Access’ Included Breast Cancer Drugs and Competitive Fall-Out 882
Table 67: Adherex’s Included Breast Cancer Drugs and Competitive Fall-Out 884
Table 68: Advanomics’ Included Breast Cancer Drugs and Competitive Fall-Out 888
Table 69: Advaxis’ Included Breast Cancer Drugs and Competitive Fall-Out 892
Table 70: AEgera’s Included Breast Cancer Drugs and Competitive Fall-Out 894
Table 71: AEterna Zentaris’ Included Breast Cancer Drugs and Competitive Fall-Out 896
Table 72: Affibody’s Included Breast Cancer Drugs and Competitive Fall-Out 900
Table 73: Affimed Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 903
Table 74: Alchemia’s Included Breast Cancer Drugs and Competitive Fall-Out 907
Table 75: Alethia Biotherapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 911
Table 76: Allos Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 913
Table 77: Alnis Biosciences’ Included Breast Cancer Drugs and Competitive Fall-Out 917
Table 78: AlphaVax’s Included Breast Cancer Drugs and Competitive Fall-Out 921
Table 79: Alseres Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 925
Table 80: Amgen’s Included Breast Cancer Drugs and Competitive Fall-Out 929
Table 81: AngioChem’s Included Breast Cancer Drugs and Competitive Fall-Out 937
Table 82: Antisoma’s Included Breast Cancer Drugs and Competitive Fall-Out 941
Table 83: Aphios’ Included Breast Cancer Drugs and Competitive Fall-Out 946
Table 84: Ariad’s Included Breast Cancer Drugs and Competitive Fall-Out 950
Table 85: ArQule’s Included Breast Cancer Drugs and Competitive Fall-Out 953
Table 86: Array BioPharma’s Included Breast Cancer Drugs and Competitive Fall-Out 958
Table 87: Ascend Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 962
Table 88: Ascepion Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 964
Table 89: Astellas’ Included Breast Cancer Drugs and Competitive Fall-Out 967
Table 90: Astex Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 972
Table 91: AstraZeneca’s Included Breast Cancer Drugs and Competitive Fall-Out 978
Table 92: Attenuon’s Included Breast Cancer Drugs and Competitive Fall-Out 986
Table 93: AVI BioPharma’s Included Breast Cancer Drugs and Competitive Fall-Out 988
Table 94: Basilea Pharmaceutica’s Included Breast Cancer Drugs and Competitive Fall-Out 992
Table 95: Bavarian Nordic’s Included Breast Cancer Drugs and Competitive Fall-Out 996
Table 96: Bayer’s Included Breast Cancer Drugs and Competitive Fall-Out 1001
Table 97: Beta Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1006
Table 98: Betagenon’s Included Breast Cancer Drugs and Competitive Fall-Out 1008
Table 99: Biogen Idec’s Included Breast Cancer Drugs and Competitive Fall-Out 1011
Table 100: BioMarin’s Included Breast Cancer Drugs and Competitive Fall-Out 1014
Table 101: Bionovo’s Included Breast Cancer Drugs and Competitive Fall-Out 1017
Table 102: BioSante’s Included Breast Cancer Drugs and Competitive Fall-Out 1020
Table 103: Biotecnol’s Included Breast Cancer Drugs and Competitive Fall-Out 1024
Table 104: Boehringer Ingelheim’s Included Breast Cancer Drugs and Competitive Fall-Out 1027
Table 105: Bristol-Myers Squibb’s Included Breast Cancer Drugs and Competitive Fall-Out 1033
Table 106: BTG’s Included Breast Cancer Drugs and Competitive Fall-Out 1042
Table 107: Callisto Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1047
Table 108: Cancer Research Technology’s Included Breast Cancer Drugs and Competitive Fall-Out 1050
Table 109: Cel-Sci’s Included Breast Cancer Drugs and Competitive Fall-Out 1053
Table 110: Celgene’s Included Breast Cancer Drugs and Competitive Fall-Out 1057
Table 111: Cell Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1063
Table 112: Celldex Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1066
Table 113: Celltrion’s Included Breast Cancer Drugs and Competitive Fall-Out 1070
Table 114: Celsion’s Included Breast Cancer Drugs and Competitive Fall-Out 1074
Table 115: Celtic Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1076
Table 116: Center of Molecular Immunology’s Included Breast Cancer Drugs and Competitive Fall-Out 1079
Table 117: Chemokine Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1082
Table 118: Chiesi’s Included Breast Cancer Drugs and Competitive Fall-Out 1085
Table 119: Chong Kun Dang’s Included Breast Cancer Drugs and Competitive Fall-Out 1089
Table 120: CompleGen’s Included Breast Cancer Drugs and Competitive Fall-Out 1091
Table 121: Curis’ Included Breast Cancer Drugs and Competitive Fall-Out 1094
Table 122: Cyclacel’s Included Breast Cancer Drugs and Competitive Fall-Out 1096
Table 123: Cylene Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1098
Table 124: Cynvec’s Included Breast Cancer Drugs and Competitive Fall-Out 1100
Table 125: CytImmune Sciences’ Included Breast Cancer Drugs and Competitive Fall-Out 1103
Table 126: Cytokinetics’ Included Breast Cancer Drugs and Competitive Fall-Out 1107
Table 127: CytRx’s Included Breast Cancer Drugs and Competitive Fall-Out 1111
Table 128: Daiichi Sankyo’s Included Breast Cancer Drugs and Competitive Fall-Out 1115
Table 129: Dainippon Sumitomo Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1120
Table 130: Debiopharm’s Included Breast Cancer Drugs and Competitive Fall-Out 1123
Table 131: Dendreon’s Included Breast Cancer Drugs and Competitive Fall-Out 1127
Table 132: Domainex’s Included Breast Cancer Drugs and Competitive Fall-Out 1130
Table 133: Dong-A’s Included Breast Cancer Drugs and Competitive Fall-Out 1134
Table 134: Dongkook Pharm’s Included Breast Cancer Drugs and Competitive Fall-Out 1137
Table 135: Douglas’ Included Breast Cancer Drugs and Competitive Fall-Out 1140
Table 136: ECI’s Included Breast Cancer Drugs and Competitive Fall-Out 1142
Table 137: Eisai’s Included Breast Cancer Drugs and Competitive Fall-Out 1145
Table 138: Elara Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1150
Table 139: ElexoPharm’s Included Breast Cancer Drugs and Competitive Fall-Out 1152
Table 140: Eli Lilly’s Included Breast Cancer Drugs and Competitive Fall-Out 1156
Table 141: Endoceutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1163
Table 142: Enkam Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1165
Table 143: EntreMed’s Included Breast Cancer Drugs and Competitive Fall-Out 1167
Table 144: Enzon’s Included Breast Cancer Drugs and Competitive Fall-Out 1170
Table 145: Epeius Biotechnologies’ Included Breast Cancer Drugs and Competitive Fall-Out 1172
Table 146: EpiCept’s Included Breast Cancer Drugs and Competitive Fall-Out 1176
Table 147: Epizyme’s Included Breast Cancer Drugs and Competitive Fall-Out 1178
Table 148: Esperance Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1180
Table 149: Etubics’ Included Breast Cancer Drugs and Competitive Fall-Out 1184
Table 150: Eucodis’ Included Breast Cancer Drugs and Competitive Fall-Out 1187
Table 151: Exelixis’ Included Breast Cancer Drugs and Competitive Fall-Out 1191
Table 152: Expression Drug Designs’ Included Breast Cancer Drugs and Competitive Fall-Out 1196
Table 153: Formula Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1199
Table 154: Fresenius’ Included Breast Cancer Drugs and Competitive Fall-Out 1203
Table 155: Galectin Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1206
Table 156: Galena Biopharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1211
Table 157: Genentech’s Included Breast Cancer Drugs and Competitive Fall-Out 1216
Table 158: Generex’s Included Breast Cancer Drugs and Competitive Fall-Out 1220
Table 159: Genmab’s Included Breast Cancer Drugs and Competitive Fall-Out 1224
Table 160: Genta’s Included Breast Cancer Drugs and Competitive Fall-Out 1227
Table 161: GenVec’s Included Breast Cancer Drugs and Competitive Fall-Out 1229
Table 162: Geron’s Included Breast Cancer Drugs and Competitive Fall-Out 1232
Table 163: Gilead Sciences’ Included Breast Cancer Drugs and Competitive Fall-Out 1236
Table 164: GlaxoSmithKline’s Included Breast Cancer Drugs and Competitive Fall-Out 1240
Table 165: GlyTag’s Included Breast Cancer Drugs and Competitive Fall-Out 1245
Table 166: Got-a-Gene’s Included Breast Cancer Drugs and Competitive Fall-Out 1249
Table 167: Gradalis’ Included Breast Cancer Drugs and Competitive Fall-Out 1251
Table 168: Harbor BioSciences’ Included Breast Cancer Drugs and Competitive Fall-Out 1254
Table 169: Heidelberg Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1257
Table 170: Hoffmann-La Roche’s Included Breast Cancer Drugs and Competitive Fall-Out 1263
Table 171: Hospira’s Included Breast Cancer Drugs and Competitive Fall-Out 1274
Table 172: Idera Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1277
Table 173: Immunocore’s Included Breast Cancer Drugs and Competitive Fall-Out 1280
Table 174: ImmunoGen’s Included Breast Cancer Drugs and Competitive Fall-Out 1283
Table 175: Immunomedics’ Included Breast Cancer Drugs and Competitive Fall-Out 1287
Table 176: ImmuPharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1290
Table 177: Immutep’s Included Breast Cancer Drugs and Competitive Fall-Out 1292
Table 178: Incyte Corporation’s Included Breast Cancer Drugs and Competitive Fall-Out 1295
Table 179: Inex’s Included Breast Cancer Drugs and Competitive Fall-Out 1298
Table 180: Infinity Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1302
Table 181: Innate Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1304
Table 182: InNexus Biotechnology’s Included Breast Cancer Drugs and Competitive Fall-Out 1308
Table 183: Inovio’s Included Breast Cancer Drugs and Competitive Fall-Out 1310
Table 184: Insmed’s Included Breast Cancer Drugs and Competitive Fall-Out 1313
Table 185: Insys Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1318
Table 186: Intarcia Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1322
Table 187: Intezyne Technologies’ Included Breast Cancer Drugs and Competitive Fall-Out 1326
Table 188: Intradigm’s Included Breast Cancer Drugs and Competitive Fall-Out 1329
Table 189: Introgen Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1332
Table 190: Ipsen’s Included Breast Cancer Drugs and Competitive Fall-Out 1336
Table 191: Isis Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1339
Table 192: Jina Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1342
Table 193: Johnson & Johnson’s Included Breast Cancer Drugs and Competitive Fall-Out 1344
Table 194: Kiadis’ Included Breast Cancer Drugs and Competitive Fall-Out 1347
Table 195: Kinex’s Included Breast Cancer Drugs and Competitive Fall-Out 1349
Table 196: Kyowa Hakko Kirin’s Included Breast Cancer Drugs and Competitive Fall-Out 1353
Table 197: Leo’s Included Breast Cancer Drugs and Competitive Fall-Out 1357
Table 198: Ligand’s Included Breast Cancer Drugs and Competitive Fall-Out 1360
Table 199: Lorus Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1363
Table 200: MacroGenics’ Included Breast Cancer Drugs and Competitive Fall-Out 1367
Table 201: Marillion Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1370
Table 202: Marina Biotech’s Included Breast Cancer Drugs and Competitive Fall-Out 1373
Table 203: Meda’s Included Breast Cancer Drugs and Competitive Fall-Out 1377
Table 204: Medarex’s Included Breast Cancer Drugs and Competitive Fall-Out 1381
Table 205: MediGene’s Included Breast Cancer Drugs and Competitive Fall-Out 1385
Table 206: MedImmune’s Included Breast Cancer Drugs and Competitive Fall-Out 1388
Table 207: Mediolanum’s Included Breast Cancer Drugs and Competitive Fall-Out 1391
Table 208: Menarini’s Included Breast Cancer Drugs and Competitive Fall-Out 1395
Table 209: Merck & Co’s Included Breast Cancer Drugs and Competitive Fall-Out 1399
Table 210: Merck KGaA’s Included Breast Cancer Drugs and Competitive Fall-Out 1402
Table 211: Merrimack’s Included Breast Cancer Drugs and Competitive Fall-Out 1405
Table 212: MetaMol Theranostics’ Included Breast Cancer Drugs and Competitive Fall-Out 1409
Table 213: Mologen’s Included Breast Cancer Drugs and Competitive Fall-Out 1412
Table 214: Nektar Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1415
Table 215: Nemod Biotherapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1418
Table 216: Neurocrine Biosciences’ Included Breast Cancer Drugs and Competitive Fall-Out 1420
Table 217: NexGenix Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1423
Table 218: Nidus Laboratories’ Included Breast Cancer Drugs and Competitive Fall-Out 1428
Table 219: NIH’s Included Breast Cancer Drugs and Competitive Fall-Out 1431
Table 220: Nimbus Discovery’s Included Breast Cancer Drugs and Competitive Fall-Out 1433
Table 221: Nippon Kayaku’s Included Breast Cancer Drugs and Competitive Fall-Out 1436
Table 222: Non-industrial source’s Included Breast Cancer Drugs and Competitive Fall-Out 1439
Table 223: Novartis’ Included Breast Cancer Drugs and Competitive Fall-Out 1446
Table 224: Novogen’s Included Breast Cancer Drugs and Competitive Fall-Out 1454
Table 225: Oasmia’s Included Breast Cancer Drugs and Competitive Fall-Out 1456
Table 226: OncoGenex Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1460
Table 227: Oncolix’s Included Breast Cancer Drugs and Competitive Fall-Out 1464
Table 228: OncoMune’s Included Breast Cancer Drugs and Competitive Fall-Out 1467
Table 229: Onconova’s Included Breast Cancer Drugs and Competitive Fall-Out 1471
Table 230: Oncothyreon’s Included Breast Cancer Drugs and Competitive Fall-Out 1474
Table 231: Oncozyme Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1477
Table 232: Orion Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1480
Table 233: OSI Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1484
Table 234: Oxford BioMedica’s Included Breast Cancer Drugs and Competitive Fall-Out 1487
Table 235: Pacific Biotech’s Included Breast Cancer Drugs and Competitive Fall-Out 1490
Table 236: Paladin Labs’ Included Breast Cancer Drugs and Competitive Fall-Out 1493
Table 237: PanaGin’s Included Breast Cancer Drugs and Competitive Fall-Out 1495
Table 238: Pantarhei Bioscience’s Included Breast Cancer Drugs and Competitive Fall-Out 1498
Table 239: Peregrine Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1500
Table 240: Pfizer’s Included Breast Cancer Drugs and Competitive Fall-Out 1506
Table 241: Pharmacyclics’ Included Breast Cancer Drugs and Competitive Fall-Out 1516
Table 242: PharmaGap’s Included Breast Cancer Drugs and Competitive Fall-Out 1518
Table 243: PharmaMar’s Included Breast Cancer Drugs and Competitive Fall-Out 1522
Table 244: Pharmexa’s Included Breast Cancer Drugs and Competitive Fall-Out 1526
Table 245: PheneX’s Included Breast Cancer Drugs and Competitive Fall-Out 1529
Table 246: Philogen’s Included Breast Cancer Drugs and Competitive Fall-Out 1531
Table 247: Pierre Fabre’s Included Breast Cancer Drugs and Competitive Fall-Out 1534
Table 248: Piramal’s Included Breast Cancer Drugs and Competitive Fall-Out 1536
Table 249: ProStrakan’s Included Breast Cancer Drugs and Competitive Fall-Out 1538
Table 250: PTC Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1541
Table 251: R&R’s Included Breast Cancer Drugs and Competitive Fall-Out 1544
Table 252: Radient Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1546
Table 253: Raptor Pharmaceutical’s Included Breast Cancer Drugs and Competitive Fall-Out 1548
Table 254: Receptor BioLogix’s Included Breast Cancer Drugs and Competitive Fall-Out 1551
Table 255: Regeneron’s Included Breast Cancer Drugs and Competitive Fall-Out 1554
Table 256: Regulon’s Included Breast Cancer Drugs and Competitive Fall-Out 1556
Table 257: RESprotect’s Included Breast Cancer Drugs and Competitive Fall-Out 1558
Table 258: Rigel’s Included Breast Cancer Drugs and Competitive Fall-Out 1560
Table 259: Samyang’s Included Breast Cancer Drugs and Competitive Fall-Out 1564
Table 260: Sanofi’s Included Breast Cancer Drugs and Competitive Fall-Out 1569
Table 261: Santaris Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1574
Table 262: Sareum’s Included Breast Cancer Drugs and Competitive Fall-Out 1576
Table 263: Savient Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1579
Table 264: Schering-Plough’s Included Breast Cancer Drugs and Competitive Fall-Out 1582
Table 265: SEEK’s Included Breast Cancer Drugs and Competitive Fall-Out 1585
Table 266: Selvita’s Included Breast Cancer Drugs and Competitive Fall-Out 1587
Table 267: Semafore Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1589
Table 268: Shenogen’s Included Breast Cancer Drugs and Competitive Fall-Out 1592
Table 269: Sigma-Tau’s Included Breast Cancer Drugs and Competitive Fall-Out 1596
Table 270: Sirnaomics’ Included Breast Cancer Drugs and Competitive Fall-Out 1598
Table 271: SRI International’s Included Breast Cancer Drugs and Competitive Fall-Out 1602
Table 272: Sun Pharma Advanced Research’s Included Breast Cancer Drugs and Competitive Fall-Out 1607
Table 273: Supratek Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1611
Table 274: Synageva BioPharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1615
Table 275: Synta Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1617
Table 276: Taiho’s Included Breast Cancer Drugs and Competitive Fall-Out 1620
Table 277: Taiwan Liposome Company’s Included Breast Cancer Drugs and Competitive Fall-Out 1625
Table 278: Takeda’s Included Breast Cancer Drugs and Competitive Fall-Out 1627
Table 279: Tapestry Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1631
Table 280: TapImmune’s Included Breast Cancer Drugs and Competitive Fall-Out 1633
Table 281: Targa Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1635
Table 282: Tau Therapeutics’ Included Breast Cancer Drugs and Competitive Fall-Out 1638
Table 283: Taxolog’s Included Breast Cancer Drugs and Competitive Fall-Out 1643
Table 284: Telik’s Included Breast Cancer Drugs and Competitive Fall-Out 1647
Table 285: Teva’s Included Breast Cancer Drugs and Competitive Fall-Out 1653
Table 286: Thallion Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1656
Table 287: Therion Biologics’ Included Breast Cancer Drugs and Competitive Fall-Out 1658
Table 288: to-BBB’s Included Breast Cancer Drugs and Competitive Fall-Out 1662
Table 289: TopoTarget’s Included Breast Cancer Drugs and Competitive Fall-Out 1665
Table 290: Tragara Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1667
Table 291: Transgene’s Included Breast Cancer Drugs and Competitive Fall-Out 1669
Table 292: Trion Pharma’s Included Breast Cancer Drugs and Competitive Fall-Out 1671
Table 293: Vaccinex’s Included Breast Cancer Drugs and Competitive Fall-Out 1673
Table 294: Vaxon Biotech’s Included Breast Cancer Drugs and Competitive Fall-Out 1676
Table 295: Verastem’s Included Breast Cancer Drugs and Competitive Fall-Out 1679
Table 296: Vernalis’ Included Breast Cancer Drugs and Competitive Fall-Out 1683
Table 297: Vical’s Included Breast Cancer Drugs and Competitive Fall-Out 1686
Table 298: Vion Pharmaceuticals’ Included Breast Cancer Drugs and Competitive Fall-Out 1689
Table 299: VioQuest’s Included Breast Cancer Drugs and Competitive Fall-Out 1692
Table 300: ViroMed’s Included Breast Cancer Drugs and Competitive Fall-Out 1696
Table 301: ViroTarg’s Included Breast Cancer Drugs and Competitive Fall-Out 1698
Table 302: Wilex’s Included Breast Cancer Drugs and Competitive Fall-Out 1700
Table 303: Wyeth’s Included Breast Cancer Drugs and Competitive Fall-Out 1703
Table 304: Xerion’s Included Breast Cancer Drugs and Competitive Fall-Out 1706
Table 305: Xoma’s Included Breast Cancer Drugs and Competitive Fall-Out 1709
Table 306: Yakult Honsha’s Included Breast Cancer Drugs and Competitive Fall-Out 1712
Table 307: YM BioSciences’ Included Breast Cancer Drugs and Competitive Fall-Out 1715
Table 308: Zensun’s Included Breast Cancer Drugs and Competitive Fall-Out 1718
Table 309: Zydus Cadila’s Included Breast Cancer Drugs and Competitive Fall-Out 1722

This report includes 247 companies (Incl. Active, Out of Business and M&A) plus their collaborators:
A&G Pharmaceutical
Abbott
Abiogen
Access
Adherex
Advanomics
Advaxis
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Alnis Biosciences
AlphaVax
Alseres Pharmaceuticals
Amgen
AngioChem
Antisoma
Aphios
Ariad
ArQule
Array BioPharma
Ascend Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVI BioPharma
Basilea Pharmaceutica
Bavarian Nordic
Bayer
Beta Pharma
Betagenon
Biogen Idec
BioMarin
Bionovo
BioSante
Biotecnol
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Research Technology
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Cel-Sci
Celsion
Celtic Pharma
Center of Molecular Immunology
Chemokine Therapeutics
Chiesi
Chong Kun Dang
CompleGen
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Dendreon
Domainex
Dong-A
Dongkook Pharm
Douglas
ECI
Eisai
Elara Pharmaceuticals
ElexoPharm
Eli Lilly
Endoceutics
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Esperance Pharmaceuticals
Etubics
Eucodis
Exelixis
Expression Drug Designs
Formula Pharmaceuticals
Fresenius
Galectin Therapeutics
Galena Biopharma
Genentech
Generex
Genmab
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
GlyTag
Got-a-Gene
Gradalis
Harbor BioSciences
Heidelberg Pharma
Hoffmann-La Roche
Hospira
Idera Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intarcia Therapeutics
Intezyne Technologies
Intradigm
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Jina Pharmaceuticals
Johnson & Johnson
Kiadis
Kinex
Kyowa Hakko Kirin
Leo
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Marina Biotech
Meda
Medarex
MediGene
MedImmune
Mediolanum
Menarini
Merck & Co
Merck KGaA
Merrimack
MetaMol Theranostics
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Neurocrine Biosciences
NexGenix Pharmaceuticals
Nidus Laboratories
NIH
Nimbus Discovery
Nippon Kayaku
Non-industrial source
Novartis
Novogen
Oasmia
OncoGenex Pharmaceuticals
Oncolix
OncoMune
Onconova
Oncothyreon
Oncozyme Pharma
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Pacific Biotech
Paladin Labs
PanaGin
Pantarhei Bioscience
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
PheneX
Philogen
Pierre Fabre
Piramal
ProStrakan
PTC Therapeutics
R&R
Radient Pharmaceuticals
Raptor Pharmaceutical
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rigel
Samyang
Sanofi
Santaris Pharma
Sareum
Savient Pharmaceuticals
Schering-Plough
SEEK
Selvita
Semafore Pharmaceuticals
Shenogen
Sigma-Tau
Sirnaomics
SRI International
Sun Pharma Advanced Research
Supratek Pharma
Synageva BioPharma
Synta Pharmaceuticals
Taiho
Taiwan Liposome Company
Takeda
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
Tau Therapeutics
Taxolog
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
to-BBB
TopoTarget
Tragara Pharmaceuticals
Transgene
Trion Pharma
Vaccinex
Vaxon Biotech
Verastem
Vernalis
Vical
Vion Pharmaceuticals
VioQuest
ViroMed
ViroTarg
Wilex
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zensun
Zydus Cadila
This report includes 470 breast cancer drugs. From Ceased to Marketed. Some examples are:
abiraterone acetate
adecatumumab
aderbasib
AE-37
AEG-35156
afatinib
aflibercept
agatolimod
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
anastrozole
Angiozyme
apricoxib
atrasentan
AUY-922
AVX-701
axitinib
AZD-4547
AZD-8931
bevacizumab
BEZ-235
BGT-226
BMS-690514
BMS-753493
BMS-754807
bortezomib
brivudine
BZL-101
Cabozantinib
canfosfamide hydrochloride
capecitabine
catumaxomab
cediranib
celecoxib
cetuximab
cilengitide
cixutumumab
CNF-2024
custirsen
dalotuzumab
dasatinib
daunorubicin
denosumab
dinaciclib
docetaxel
dovitinib lactate
doxifluridine
doxorubicin
E-75
elsamitrucin
endoxifen
eniluracil
entinostat
enzastaurin hydrochloride
epirubicin
erlotinib
ertumaxomab
estetrol
everolimus
exemestane
Exherin
F16-IL2
fadrozole
figitumumab
formestane
fulvestrant
ganitumab
gimatecan
glembatumumab vedotin
goserelin
GVAX
Her-2/Neu peptides
icotinib hydrochloride
idronoxil
imetelstat
IMP-321
INCB-028060
iniparib
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
irosustat
ispinesib mesylate
lapatinib ditosylate
lasofoxifene
letrozole
leucine-doxorubicin
leuprorelin
linifanib
LipoVIL12
lonafarnib
lonaprisan
LOR-2040
MetXia
milataxel
mitoxantrone
MKC-1
MM-111
MM-121
motesanib diphosphate
MVA-BN Her-2 vaccine
Nab-docetaxel
neratinib
NK-012
oblimersen sodium
olaparib
P276-00
paclitaxel
paclitaxel polyglumex
panobinostat
pazopanib hydrochloride
PD-0332991
pemetrexed disodium
perifosine
pertuzumab
pixantrone
pralatrexate
PTC-299
raloxifene hydrochloride
ramucirumab
Reximmune-C
Rexin-G
ridaforolimus
romidepsin
sagopilone
seliciclib
SN-38
sorafenib tosylate
SU-6668
talminogene laherparepvec
tamoxifen
tamoxifen, oral liquid
TAS-108
temsirolimus
Tenarad
TG-4010
tipifarnib
tivozanib
toremifene citrate
trastuzumab
trastuzumab emtansine
triciribine phosphate
trilostane
triptorelin pamoate
TroVax
TS-1
vandetanib
varlitinib
WX-671
XL-147
XL-647
XL-765
YM-155
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others.
    To find out more about Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Apoptotic Therapeutics in Oncology - Where to Commercialize?
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning. Learn More


Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
This report is an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Antibodies and Peptides
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two compound strategies of Antibodies and Peptides. Learn More


Drug Target Atlas in Oncology
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More